Graft vs Host Disease

Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic haematopoietic cell transplantation from unrelated donors. Here is the latest research.


July 28, 2020
Open Access

Allogeneic Stem Cell Transplantation for patients with lower risk MDS

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Polona NovakNicolaus Kröger
August 5, 2020

Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors

European Journal of Haematology
Jean-Sébastien ClaveauJean Roy
July 30, 2020
Comment / Editorial

Ruxolitinib for Acute Graft-versus-Host Disease

The New England Journal of Medicine
Alois Gratwohl
July 29, 2020

Operational Tolerance in Intestinal Transplantation

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Alexander KroemerThomas M Fishbein
July 28, 2020
Open Access

Commentary: Ocular surface involvement heralds graft-versus-host disease: Time to act

Indian Journal of Ophthalmology
Purvasha Narang, Sayan Basu
August 1, 2020
Open Access

Early Outcomes of Ruxolitinib in the Treatment of Steroid Refractory Graft-versus-host Disease on Liver Transplant Recipients

Transplantation
Sunilkumar KakadiaEmmanouil Giorgakis
August 5, 2020

Impact of anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Leonardo Javier ArcuriAntonio Guilherme Fonseca Pacheco
August 1, 2020
Review
Open Access

Large-Scale Expansion of Human Mesenchymal Stem Cells

Stem Cells International
Muhammad Najib Fathi Bin HassanJia Xian Law
July 28, 2020

Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants

The Journal of Clinical Investigation
James W Young

Sign up to follow this feed and discover related papers.

Related Feeds

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Exosomes & Tumor Environment

Several studies have reported the role of exosomes as important mediators of angiogenesis, metastasis, and immune modulation. Exosomes also have the potential to be used as biomarkers for clinical predictions. Here is the latest research on exosomes and the tumor microenvironment.

Graft Rejection

Graft rejection occurs when the donor's grafted tissue is rejected by the recipient's immune system, destroying the transplanted tissue. Discover the latest research on graft rejection here.

Immune Therapies In Cancer

Immunotherapy in cancer is used to help the immune system fight against invading cancer cells. It is used to slow the progression of the disease and prevent metastasis while enhancing the immune response. There are different types, including monoclonal antibodies and checkpoint inhibitors. Here is the latest research on immune therapies in cancer.

Immuno-Oncology

Immuno-oncology (or cancer immunotherapy) is the artificial stimulation of the immune system to treat cancer, improving on the immune system's natural ability to fight cancer. It exploits the fact that cancer cells often have tumor antigens, molecules on their surface that can be detected by the antibody proteins of the immune system, binding to them. The tumor antigens are often proteins or other macromolecules. Normal antibodies bind to external pathogens, but the modified immunotherapy antibodies bind to the tumor antigens marking and identifying the cancer cells for the immune system to inhibit or kill. Discover the latest research on immuno-oncology here.

Immunosuppression

Immunosuppression trends for solid organ transplantation have undergone a perceptible shift over the past decade. Discover the latest research on immunosuppression here.

Metastatic Malignancy Treatments

Treatment of metastatic cancers depends on the type of cancer and the severity of the disease. The regime often includes medications such as chemotherapy or hormone therapy, but may also include immunotherapy, radiation therapy, surgery or a combination. Discover the latest research on metastatic cancer treatments here.

Tumor Evasion of the Immune System

Tumor evasion of the immune system includes cells that operate their own growth and develop various strategies to escape from immune surveillance. Discover the latest research on tumor evasion of the immune system here.

Tumor Vaccines

Tumor vaccines offer the potential for preventing cancer in high-risk individuals, preventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tumor interaction to mitigate the progression of advanced cancers. Discover the latest research on tumor vaccines here.

© 2020 Meta ULC. All rights reserved
/feed-previews/graft-vs-host-disease/20952976-c76e-40c1-a801-01217ab8745e